MELBOURNE, Australia—A short two months after announcing that it was restructuring its U.S.-based operations and laying off half its U.S. staff, RNAi specialist Benitec announced it would completely close its Mountain View, Calif. operations. In doing so, the company hopes to cut its monthly operating expendi­tures by $250,000 by retrenching its IP and drug development operations back to Australia, where the company was founded.

 

In a prepared statement, company Chairman Peter Francis states: "The directors have imple­mented these changes to reduce the company's cash burn in the current environment. Our focus now is the preservation of the company's intel­lectual property and the placement of our in-house clinical program on hold. We will con­tinue our efforts to raise capital and transact on RNAi opportunities in the best interests of our shareholders."

 

Dr. Kenneth Krul, a market analyst for Kalorama Information, seemed less upbeat about the move. "As for any benefits the company will reap by closing its U.S. operations, there are the cost savings but it is not a certainty that these will help Benitec complete their mission," he says. "It would seem to me that the company is in some heavy financial seas, and that product development might further be curtailed if the financing isn't there."

 

The retrenchment will also see the departure of the U.S. operation's CEO Sara Cunningham and CFO Mike Catelani, who had only taken their posts in early 2005. According to Francis, the two will be involved in the transition and repatriation efforts to ensure the process runs smoothly.

 

The move comes at a time when the entire RNAi marketspace is rapidly evolving. At the same time that discovery companies and reagent suppliers are swing­ing deal after deal or collaborat­ing with almost anyone who comes along—for example, the recent collaboration between Abbott and Dharmacon and the expanded therapeutics deal between Merck and Alnylam—the industry is also facing waves of litigation, as com­panies try to shake out complex IP issues.

 

Indicative of this period of flux, Krul described the nucleic acids therapeutics market as "a market in suspension waiting for the appli­cation of an accelerating force" in a recent market report.

 

"We know that there are plenty of opportunities for nucleic acid therapeutics," he says. "The prob­lem is that we don't know the core information, like what the targets are and how to get to them without disrupting other functions. While the action of nucleic acid therapeu­tics is quite specific for targets, the targets themselves may be involved in more than one function.

 

"The application that is most likely to succeed first and biggest is in viral therapeutics—such as Benitec's potential HIV therapeu­tic," he continues. "But even that has yet to be seen as a solid appli­cation since we're all waiting for a major application to emerge."